[ad_1]
AstraZeneca has signed a strategic agreement to expand its existing partnership with a healthcare company in Abu Dhabi to locally manufacture innovative medicines.
AstraZeneca announces expansion of current partnership with artificial intelligence-based company G42 Healthcare, signing agreement to manufacture innovative medicines in Abu Dhabi, doubling its size in line with Abu Dhabi’s industrial strategy manufacturing by 2031.
Manufacturing Drugs in Abu Dhabi
The agreement focuses on cooperation in four key areas, including localizing innovative industries, research and developmentGlobally, innovation, sustainability and development elevate the United Arab Emirates (UAE) as a global hub for the industries of the future.
Sameh ElFangary, AstraZeneca GCC and Pakistan Cluster President, said: “AstraZeneca is…now leveraging our existing partnership with G42 Healthcare…and accelerating collaboration on local manufacturing, research, innovation and sustainable development . I believe this partnership will greatly facilitate the development of a sustainable health ecosystem that can transform patient outcomes.”
Abu Dhabi’s Department of Health (DoH) noted that the two parties will work closely to boost exports and develop cutting-edge science and activities to support the delivery of life-changing medicines to patients in the UAE.
Commenting on AstraZeneca’s decision to support the localization and manufacturing of medicines in Abu Dhabi, Dr Jamal Mohammed Al Kaabi, Deputy Minister of Health of Abu Dhabi shared: “Due to the industry’s growth potential, international appetite and investment opportunities in the biopharmaceutical sector and healthcare value chains continue to emerge in Abu Dhabi.”
According to the Abu Dhabi Department of Health, the strategic agreement will expand Abu Dhabi’s footprint in life sciences research and development and foster innovation in all healthcare sectors.
What drug do you think AstraZeneca is (this) should prioritize manufacturing in Abu Dhabi?
[ad_2]
Source link